Annual Operating Expenses
$42.00 M
+$5.26 M+14.33%
September 30, 2024
Summary
- As of February 8, 2025, CTXR annual total operating expenses is $42.00 million, with the most recent change of +$5.26 million (+14.33%) on September 30, 2024.
- During the last 3 years, CTXR annual operating expenses has risen by +$18.46 million (+78.46%).
- CTXR annual operating expenses is now at all-time high.
Performance
CTXR Operating Expenses Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Quarterly Operating Expenses
$11.05 M
+$416.30 K+3.91%
September 30, 2024
Summary
- As of February 8, 2025, CTXR quarterly total operating expenses is $11.05 million, with the most recent change of +$416.30 thousand (+3.91%) on September 30, 2024.
- Over the past year, CTXR quarterly operating expenses has increased by +$416.30 thousand (+3.91%).
- CTXR quarterly operating expenses is now at all-time high.
Performance
CTXR Quarterly Operating Expenses Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Operating Expenses Formula
Operating Expenses = Selling, General & Administrative (SG&A) Expenses + Research & Development (R&D) Expenses + Depreciation & Amortization + Other Operating Expenses
CTXR Operating Expenses Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly |
|---|---|---|
| 1 y1 year | +14.3% | +3.9% |
| 3 y3 years | +78.5% | +3.9% |
| 5 y5 years | +169.2% | +3.9% |
CTXR Operating Expenses Highs & Lows
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | |
|---|---|---|---|---|---|
| 3 y | 3-year | at high | +78.5% | at high | +52.4% |
| 5 y | 5-year | at high | +169.2% | at high | +166.9% |
| alltime | all time | at high | >+9999.0% | at high | >+9999.0% |
Citius Pharmaceuticals Operating Expenses History
| Date | Annual | Quarterly |
|---|---|---|
| Sep 2024 | $42.00 M(+14.3%) | $11.05 M(+3.9%) |
| Jun 2024 | - | $10.63 M(-3.1%) |
| Mar 2024 | - | $10.97 M(+17.4%) |
| Dec 2023 | - | $9.34 M(-7.7%) |
| Sep 2023 | $36.73 M(+10.3%) | $10.12 M(+16.8%) |
| Jun 2023 | - | $8.67 M(-18.8%) |
| Mar 2023 | - | $10.69 M(+47.4%) |
| Dec 2022 | - | $7.25 M(-4.0%) |
| Sep 2022 | - | $7.55 M(-15.3%) |
| Sep 2022 | $33.32 M(+41.6%) | - |
| Jun 2022 | - | $8.92 M(+17.5%) |
| Mar 2022 | - | $7.59 M(-18.0%) |
| Dec 2021 | - | $9.26 M(+78.0%) |
| Sep 2021 | $23.53 M(+32.9%) | $5.20 M(-13.1%) |
| Jun 2021 | - | $5.98 M(+42.9%) |
| Mar 2021 | - | $4.19 M(-48.7%) |
| Dec 2020 | - | $8.16 M(+97.0%) |
| Sep 2020 | $17.71 M(+13.5%) | $4.14 M(-11.7%) |
| Jun 2020 | - | $4.69 M(+5.8%) |
| Mar 2020 | - | $4.43 M(-0.3%) |
| Dec 2019 | - | $4.45 M(+21.6%) |
| Sep 2019 | $15.60 M(+13.1%) | $3.66 M(-17.4%) |
| Jun 2019 | - | $4.43 M(+21.5%) |
| Mar 2019 | - | $3.64 M(-6.0%) |
| Dec 2018 | - | $3.87 M(+5.8%) |
| Sep 2018 | $13.79 M | $3.66 M(+81.4%) |
| Jun 2018 | - | $2.02 M(-58.5%) |
| Mar 2018 | - | $4.87 M(+50.1%) |
| Date | Annual | Quarterly |
|---|---|---|
| Dec 2017 | - | $3.24 M(+35.0%) |
| Sep 2017 | $9.99 M(+34.1%) | $2.40 M(+6.5%) |
| Jun 2017 | - | $2.26 M(-11.3%) |
| Mar 2017 | - | $2.54 M(-8.7%) |
| Dec 2016 | - | $2.78 M(-18.2%) |
| Sep 2016 | $7.45 M(+130.6%) | $3.41 M(+60.2%) |
| Jun 2016 | - | $2.13 M(+216.6%) |
| Mar 2016 | - | $671.60 K(-46.0%) |
| Dec 2015 | - | $1.24 M(+28.5%) |
| Sep 2015 | $3.23 M(>+9900.0%) | $968.40 K(+25.2%) |
| Jun 2015 | - | $773.70 K(+27.1%) |
| Mar 2015 | - | $608.90 K(-30.7%) |
| Dec 2014 | - | $878.90 K(>+9900.0%) |
| Jun 2014 | - | $1300.00(-97.4%) |
| Mar 2014 | - | $49.80 K(-90.0%) |
| Dec 2013 | - | $499.20 K(+3295.9%) |
| Sep 2013 | $28.10 K(+43.4%) | $14.70 K(+332.4%) |
| Jun 2013 | - | $3400.00(-63.4%) |
| Mar 2013 | - | $9300.00(+1450.0%) |
| Dec 2012 | - | $600.00(-86.7%) |
| Sep 2012 | $19.60 K(-23.4%) | $4500.00(-27.4%) |
| Jun 2012 | - | $6200.00(-7.5%) |
| Mar 2012 | - | $6700.00(+204.5%) |
| Dec 2011 | - | $2200.00(-8.3%) |
| Sep 2011 | $25.60 K | $2400.00(-66.2%) |
| Jun 2011 | - | $7100.00(0.0%) |
| Mar 2011 | - | $7100.00(-21.1%) |
| Dec 2010 | - | $9000.00 |
FAQ
- What is Citius Pharmaceuticals annual total operating expenses?
- What is the all time high annual operating expenses for Citius Pharmaceuticals?
- What is Citius Pharmaceuticals annual operating expenses year-on-year change?
- What is Citius Pharmaceuticals quarterly total operating expenses?
- What is the all time high quarterly operating expenses for Citius Pharmaceuticals?
- What is Citius Pharmaceuticals quarterly operating expenses year-on-year change?
What is Citius Pharmaceuticals annual total operating expenses?
The current annual operating expenses of CTXR is $42.00 M
What is the all time high annual operating expenses for Citius Pharmaceuticals?
Citius Pharmaceuticals all-time high annual total operating expenses is $42.00 M
What is Citius Pharmaceuticals annual operating expenses year-on-year change?
Over the past year, CTXR annual total operating expenses has changed by +$5.26 M (+14.33%)
What is Citius Pharmaceuticals quarterly total operating expenses?
The current quarterly operating expenses of CTXR is $11.05 M
What is the all time high quarterly operating expenses for Citius Pharmaceuticals?
Citius Pharmaceuticals all-time high quarterly total operating expenses is $11.05 M
What is Citius Pharmaceuticals quarterly operating expenses year-on-year change?
Over the past year, CTXR quarterly total operating expenses has changed by +$416.30 K (+3.91%)